CeQur Announces Positive Results for Its Insulin Delivery Device

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, presented initial data from a study of the company’s PaQ Insulin Delivery Device at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France. The data suggest that PaQ is a safe, highly satisfying alternative to multiple daily insulin injections (MDI) for people with type 2 diabetes – many of whom need new tools to help them achieve better glycemic control.
 
“This study demonstrated that simple infusion with a device such as PaQ is a valid approach for people with type 2 diabetes who are dependent on multiple daily insulin injections,” said Dr. Julia Mader of the Division of Endocrinology and Metabolism, Medical University of Graz, who presented the data. “This is very exciting because it means we will have a new tool to help our patients with type 2 diabetes overcome some of the obstacles that currently prevent them from effectively managing their disease.”
 
Data suggest that approximately 50 percent of insulin-requiring individuals do not achieve appropriate glycemic control. Poor glycemic control is associated with additional health-care costs and high risk of disabling complications, including diabetic retinopathy, chronic kidney disease and cardiovascular disease. Half of all patients requiring MDIs report that they intentionally skip doses because they consider the injections embarrassing, inconvenient, painful, and/or disruptive to their daily activities.
 
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor.
 
CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The company is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. CeQur was established in January 2008.